effects of taurine in traumatic brain injury

Effects of Taurine Powder Supplementation on Inflammatory Markers and Clinical Outcomes in Traumatic Brain Injury Patients Admitted to the Intensive Care Unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180514039657N1

Enrollment

Registered

2018-06-22

Start date

2018-06-10

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

traumatic brain injury. Diffuse traumatic brain injury

Interventions

Intervention 1: Intervention group: standard entrameal of karen pharma with taurine powder with a dose 30 mg/kg in two divided doses per day for 14 days. Intervention 2: Control group: standard entram

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: At least 18 years old GCS=6-12 traumatic brain injury patients receive entral nutrition

Exclusion criteria

Exclusion criteria: Taking anti-inflammatory drugs or corticosteroids before entering the study Patients with liver or kidney disorders Pregnant or lactating women Patients with Congenital Amino Acid Metabolism Disorder Failure to provide more than 60% of the energy and protein requirement calculated through entral nutrition in the first week

Design outcomes

Primary

Measure	Time frame
High sensitive C-Reactive Protein. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Tumor Necrosis Factor-alpha. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Interleukin-6. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Interleukin-10. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Weight. Timepoint: The beginning and end of the study. Method of measurement: Patient bedside scale.;Clinical outcome measurement. Timepoint: day 1,7,14. Method of measurement: Sequential Organ Failure Assessment(SOFA) score.;Disease severity. Timepoint: day 1,14. Method of measurement: APACHEII score.	—

Measure

Time frame

High sensitive C-Reactive Protein. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Tumor Necrosis Factor-alpha. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Interleukin-6. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Interleukin-10. Timepoint: The beginning and end of the study. Method of measurement: ELISA.;Weight. Timepoint: The beginning and end of the study. Method of measurement: Patient bedside scale.;Clinical outcome measurement. Timepoint: day 1,7,14. Method of measurement: Sequential Organ Failure Assessment(SOFA) score.;Disease severity. Timepoint: day 1,14. Method of measurement: APACHEII score.

—

Secondary

Measure	Time frame
30-day mortality. Timepoint: day 30. Method of measurement: Contact with patient's family.;Length of stay to ICU. Timepoint: daily. Method of measurement: observation.;Malnutrition. Timepoint: The beginning and end of the study. Method of measurement: subjective global assessment.;Dependence on ventilator. Timepoint: daily. Method of measurement: Counting the number of ventilator attachment days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahsa Vahdat

Ahvaz University of Medical Sciences

vahdat.m@ajums.ac.ir+98 61 3321 4578

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 22, 2026